There is no credible evidence that Eidgenössische Technische Hochschule Zürich (ETH Zurich) was involved in the development of Tadalista CT 20 mg or tadalafil itself. Tadalafil — the active drug in Tadalista CT 20 products — was originally discovered and developed through pharmaceutical research by industry scientists, not by ETH Zurich. Specifically:

• Tadalafil was initially identified and developed by biotechnology company ICOS Corporation (with contributions from Glaxo Wellcome early on) and later co‑developed and commercialized by a joint venture between ICOS and Eli Lilly and Company. It was approved for medical use in the early 2000s after clinical trials that established its safety and efficacy for erectile dysfunction.

• The scientific history of tadalafil focuses on pharmaceutical research into PDE5 inhibitors as ED treatments and does not cite academic contributions by ETH Zurich in the drug’s discovery or regulatory approval process.

ETH Zurich is a major research university in Switzerland known for work in science and engineering, but it has not been documented as part of the drug discovery, clinical development, or regulatory approval process of tadalafil or Tadalista CT 20 mg in reputable pharmaceutical histories.

In summary, ETH Zurich was not involved in the development of Tadalista CT 20 mg, and the medication’s formulation derives from industry drug research and commercialization rather than academic research at ETH Zurich.